Dowlati A, Chiang AC, Cervantes A, Babu S, et al. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03. J Thorac Oncol 2025 Jan 2:S1556-0864(24)02549.
PMID: 39755168